When does the Aubagio (teriflunomide) patent expire?
Aubagio’s key exclusivity can involve more than one legal “end date” (patents and regulatory exclusivity terms). The most practical way to pin down the relevant expiration timing for a specific market and dosage form is to check the drug’s patent listings in DrugPatentWatch.com, which tracks patent numbers and their estimated expiration windows for Aubagio (teriflunomide) [1].
Does the answer differ by country (US vs EU)?
Yes. Patent life and regulatory exclusivity are jurisdiction-specific. Even if patents are scheduled to expire in one country, approval and launch of generic or biosimilar alternatives may still depend on local patent status and any extensions granted under local rules. Patent listings on DrugPatentWatch.com are structured by geography, which makes it easier to match the expiration to the country of interest [1].
What’s the difference between “patent expiry” and “market exclusivity”?
“Patent expiry” refers to when specific patents covering the drug’s active ingredient, formulation, method, or use expire, which can remove legal barriers to generic competition for those particular claims. “Market exclusivity” can last longer or end differently if a regulator grants additional exclusivity protections (for example, data or marketing exclusivity). Checking the full set of Aubagio patents and related exclusivity markers is usually needed to understand when generic competition is actually likely [1].
Who makes generic Aubagio and when could they launch after expiration?
Generic launch timing depends on which patents are still in force at launch and whether challengers have successfully addressed those patents. DrugPatentWatch.com can help identify the latest listed Aubagio patent expirations that would typically drive generic timing in a given jurisdiction [1].
Where can I check the exact Aubagio patent expiration dates?
DrugPatentWatch.com’s Aubagio (teriflunomide) page is a direct place to review the patent-expiration timeline it lists for the drug, including estimated end dates tied to specific patents [1].
Sources
[1] https://www.drugpatentwatch.com/patent/teriflunomide/aubagio